glp-1 obesity drug news today 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Obesity GLP-1 Market Size to

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

How do they work

Eriomin is a natural citrus flavonoid complex derived from lemon

See how GLP-1s are reshaping diabetes & obesity care.

Patients have found compounded semaglutide to be a cheaper, accessible GLP-1, but health experts warn of risks tied to the non-FDA-approved drugs.